Clinical trials: Chemotherapy-induced Febrile Neutropenia
Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
This study aims to analyze the effects of long-acting versus short-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian cancer patients.
- Conditions
- Chemotherapy-induced Neutropenia, Febrile Neutropenia, Drug-Induced, Epithelial Ovarian Cancer, Colony Stimulating Factors Adverse Reaction
- Trial name
- NCT04101760
- Testing
- Long-acting granulocyte colony stimulating factor, Short-acting granulocyte colony stimulating factor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lei Li
Fever, Sweats, and Hot Flashes, Neutropenia
Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy
RATIONALE: Antibiotics may decrease the side effects of neutropenia and fever caused by chemotherapy. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and…
- Conditions
- Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003739
- Testing
- filgrastim
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 67 people
- Sponsor
- Children's Oncology Group
Early Stage Breast Cancer
A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)
In patients with early-stage breast cancer, chemotherapy has substantially improved survival rates for breast cancer patients. Improvements in outcomes, however, are compromised by the considerable toxicities associated with…
- Trial name
- React-G (NCT02428114)
- Where
- 2 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Ottawa Hospital Research Institute
C15.378
Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients.
The combination of amoxicillin-clavulanate (AC) and a fluoroquinolone (FQ) is currently recommended for the treatment for outpatients with hematologic malignancies presenting with chemotherapy-induced fever (CIF), if the expected…
- Trial name
- AC-CIF (NCT07483736)
- Testing
- amoxicillin-clavulanate, Amoxicillin-clavulanate ciprofloxacin
- Where
- 16 sites in France
- Volunteers
- 1,526 people
- Sponsor
- Versailles Hospital
Chemotherapy-Induced Febrile Neutropenia
Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
The goal of this real-world study is to compare the efficacy and safety of QL0605 administered 24 hours and 48 hours after chemotherapy in breast cancer patients.
- Trial name
- NCT06616571
- Testing
- QL0605(PEG-rhG-CSF)
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy
Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia
This study aim to find the best option for children having cancer who develop low immunity state due to chemotherapy
- Conditions
- Febrile Neutropenia, Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy, Febrile Neutropenia, Drug-Induced, G-CSF
- Trial name
- AGF-FN (NCT06988826)
- Testing
- G-CSF, Antibiotics only
- Volunteers
- 150 people
- Sponsor
- King Edward Medical University
Chemotherapy-induced Febrile Neutropenia
Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.
This is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy.
- Trial name
- NCT01813721
- Where
- 90 sites in Australia, Austria and 9 more
- Volunteers
- 1,007 people
- Sponsor
- Amgen
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
Gynecologic Cancer, Myelosuppression Adult
G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients
This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients.
- Conditions
- Gynecologic Cancer, Myelosuppression Adult, Febrile Neutropenia, Chemotherapy-induced Neutropenia
- Trial name
- NCT03793205
- Testing
- Long-acting G-CSF, Short-acting G-CSF
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lei Li
Febrile Neutropenia, Solid Tumor
Shared Health Information System for Febrile Neutropenia
The use of e-health in improving the quality of health services is a rapidly expanding research area, in particular its usefulness in patient management of the home-hospital care pathway.
- Conditions
- Febrile Neutropenia, Solid Tumor, Hematologic Neoplasms
- Trial name
- NEUTROSIS (NCT03087227)
- Testing
- NEUTROSIS
- Where
- 3 sites in France
- Volunteers
- 121 people
- Sponsor
- Marie-Helene METZGER
Breast Neoplasms, Chemotherapy-Induced Febrile Neutropenia
Efficacy and Safety Study With MYL-1401H and Neulasta
This is a Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and Neulasta (Pegfilgrastim) in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy.
- Trial name
- NCT02467868
- Testing
- MYL-1401H, Neulasta
- Where
- 36 sites in Bulgaria, Georgia and 4 more
- Volunteers
- 193 people
- Sponsor
- Mylan Inc.
Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female
Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy
To evaluate the efficacy, safety, and immunogenicity of PEG-G-CSF Injection (Kexing Biopharmaceutical Co., Ltd.) for the prevention of neutropenia after chemotherapy, using the PEG-G-CSF Injection ( Neulasta®, Amgen Europe B.V.)…
- Trial name
- NCT06711523
- Testing
- PEG-G-CSF injection (Kexing Biopharmaceutical Co., Ltd.), PEG-G-CSF injection (Neulasta®，Amgen Europe B.V.)
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Pediatric Cancer, Febrile Neutropenia
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
In this pilot study the feasibility continous recording of vital signs in pediatric patients under chemotherapy for cancer, is studied.
- Conditions
- Pediatric Cancer, Febrile Neutropenia, Oncology, Chemotherapy-induced Neutropenia
- Trial name
- NCT04914702
- Testing
- Everion®, CORE®
- Where
- 2 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Myeloid Leukemia, Neutropenia
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure after induction chemotherapy for patients with acute myeloid leukemia (AML).
- Conditions
- Acute Myeloid Leukemia, Neutropenia, Infection
- Trial name
- NCT02282215
- Testing
- CLT-008, G-CSF
- Where
- 22 sites in United States
- Volunteers
- 163 people
- Sponsor
- Cellerant Therapeutics
Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection.
- Conditions
- Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia, Chemotherapy-Induced Febrile Neutropenia, Pediatric Cancer
- Trial name
- NCT03823950
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Mississippi Medical Center
Chemotherapy-Induced Febrile Neutropenia
Safety and Efficacy of Ambulatory Versus In-hospital Antibiotic Treatment in Children With Febrile Neutropenia
Febrile neutropenia (FN) continues to be the infectious complication that most commonly requires hospitalization in pediatric cancer patients undergoing chemotherapy.
- Trial name
- NCT04000711
- Testing
- Outpatient oral treatment., Inpatient intravenous treatment.
- Volunteers
- 117 people
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Pediatric Cancer, Febrile Neutropenia
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
In this pilot study the feasibility of continous monitoring of health data with a small, on-skin wearable device (the Everion®, by Biovotion, Zurich) in pediatric patients under chemotherapy for cancer, is studied.
- Conditions
- Pediatric Cancer, Febrile Neutropenia, Chemotherapy-induced Neutropenia, Oncology
- Trial name
- NCT04134429
- Testing
- Everion
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Solid Tumors, Malignant Hemopathy
Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents
The main aim of the study is to assess the safety of Nivestim® treatment in patients treated with neutropenia-inducing chemotherapy for a malignant disease, solid tumor or a malignant hemopathy.
- Conditions
- Solid Tumors, Malignant Hemopathy, Chemotherapy-induced Febrile Neutropenia (FN)
- Trial name
- NCT01574235
- Testing
- Nivestim®
- Where
- 87 sites in France
- Volunteers
- 2,114 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Patient Preference, Febrile Neutropenia, Drug-Induced
Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim
Febrile neutropenia (NF) is a common serious complication of cancer chemotherapy. Outpatient management of chemotherapy treatments is made essential by the volume of patients treated, respect for their quality of life and the…
- Conditions
- Patient Preference, Febrile Neutropenia, Drug-Induced, Patient Satisfaction
- Trial name
- PELGRAZ (NCT05910164)
- Testing
- PELGRAZ prefilled syringe or PELGRAZ prefilled pen
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Institut Rafael
Chemotherapy-induced Neutropenia
Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2).
- Trial name
- NCT02104830
- Testing
- Empegfilrastim 6 mg, Filgrastim, Empegfilrastim 7.5 mg
- Where
- 13 sites in Russia
- Volunteers
- 135 people
- Sponsor
- Biocad